L-Lysine, CAS# 657-27-2, is a amino acid manufactured through fermentation, available as yellow powder. L-Lysine is widely used as nutrition supplements. It is widely accepted as safe food additive in many countries.
No significant side effects reported. L-Lysine can cause stomach pain and diarrhea in specific groups of individuals.
As L-Lysine is widely known as safe, there is no limit on dosage of intake. However, we still recommend consumers to consult professionals before using large quantity of L-Lysine for long period.
Special groups refer to newborns, children, pregnant and any other applicable vulnerable groups.
There is no evidence that L-Lysine could have any negative effects on these vulnerable groups. It should be safe to use L-Lysine in food for newborns and pregnant. However, we still recommend consumers to consult professionals before using large quantity of L-Lysine for long period in food for newborns or pregnant.
Generally recognized as safe(GRAS) is a FDA designation that a specific substance or ingredient is generally considered safe by experts, and so is exempted from the usual Federal Food, Drug, and Cosmetic Act (FFDCA) food additive tolerance requirements. L-Lysine is considered safe by FDA according to existing data and granted GRAS status.
No breaking news or public health crises reported about L-Lysine reported up to now.
* Want to report news about this ingredient, please send email to email@example.com. Your knowledge can help us to uncover more truthes about food ingredients to customers.
1. In vivo toxicity and biodistribution of intraperitoneal and intravenous poly-L-lysine and poly-L-lysine/poly-L-glutamate in rats. [J Mater Sci Mater Med. 2014 May]
Author: Isaksson K, Akerberg D, Posaric-Bauden M, Andersson R, Tingstedt B.
2. Enhanced epsilon-poly-L-lysine production from Streptomyces ahygroscopicus by a combination of cell immobilization and in situ adsorption. [J Microbiol Biotechnol. 2012 Sep]
Author: Liu S, Wu Q, Zhang J, Mo S, Yang X, Xiao C
3. In vivo distribution of avidin-conjugated MX35 and (211)At-labeled, biotinylated poly-L-lysine for pretargeted intraperitoneal α-radioimmunotherapy. [Cancer Biother Radiopharm. 2011 Dec]
Author: Frost SH, Bäck T, Chouin N, Jensen H, Hultborn R, Jacobsson L, Lindegren S.
4. Study on galactose-poly(ethylene glycol)-poly(L-lysine) as novel gene vector for targeting hepatocytes in vitro. [J Biomater Sci Polym Ed. 2012]
Author: Hu HM, Zhang X, Zhong NQ, Pan SR.
5. Isolation and characterization of a novel ε-poly-L-lysine producing strain: Streptomyces griseofuscus. [J Ind Microbiol Biotechnol. 2011 Apr]
Author: Li S, Tang L, Chen X, Liao L, Li F, Mao Z.